Roth Capital Has Negative Outlook for Electromed Q2 Earnings

Electromed, Inc. (NYSE:ELMD) – Equities research analysts at Roth Capital lowered their Q2 2026 earnings per share (EPS) estimates for shares of Electromed in a research note issued to investors on Wednesday, November 12th. Roth Capital analyst K. Bauser now anticipates that the company will post earnings of $0.25 per share for the quarter, down from their prior estimate of $0.27. Roth Capital has a “Buy” rating and a $36.00 price objective on the stock. Roth Capital also issued estimates for Electromed’s Q3 2026 earnings at $0.25 EPS, FY2026 earnings at $1.05 EPS and FY2027 earnings at $1.25 EPS.

Other analysts also recently issued research reports about the stock. Lake Street Capital began coverage on shares of Electromed in a report on Wednesday, August 27th. They issued a “buy” rating and a $36.00 target price for the company. Loop Capital set a $36.00 price target on Electromed in a research report on Wednesday, August 27th. Finally, Zacks Research cut Electromed from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 27th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $36.50.

Electromed Trading Down 5.0%

Electromed stock traded down $1.31 during trading on Friday, hitting $25.04. 7,093 shares of the company were exchanged, compared to its average volume of 77,355. The company has a market capitalization of $209.74 million, a P/E ratio of 33.39 and a beta of 0.40. The business’s 50 day moving average is $24.60 and its 200 day moving average is $21.98. Electromed has a 52 week low of $17.73 and a 52 week high of $35.56.

Insider Activity

In other news, Director Andrew Summers sold 3,153 shares of the company’s stock in a transaction on Thursday, September 11th. The stock was sold at an average price of $24.42, for a total transaction of $76,996.26. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 10.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Electromed

Large investors have recently added to or reduced their stakes in the company. Millennium Management LLC lifted its holdings in Electromed by 362.7% during the first quarter. Millennium Management LLC now owns 194,519 shares of the company’s stock valued at $4,641,000 after purchasing an additional 152,480 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Electromed by 128.3% in the second quarter. Geode Capital Management LLC now owns 155,540 shares of the company’s stock worth $3,421,000 after purchasing an additional 87,401 shares in the last quarter. Acadian Asset Management LLC boosted its holdings in Electromed by 25.2% in the 1st quarter. Acadian Asset Management LLC now owns 267,975 shares of the company’s stock worth $6,388,000 after buying an additional 53,872 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Electromed by 117.7% during the second quarter. JPMorgan Chase & Co. now owns 64,371 shares of the company’s stock worth $1,416,000 after acquiring an additional 34,799 shares in the last quarter. Finally, Jane Street Group LLC grew its position in shares of Electromed by 136.3% in the first quarter. Jane Street Group LLC now owns 56,263 shares of the company’s stock valued at $1,342,000 after purchasing an additional 32,456 shares in the last quarter. Hedge funds and other institutional investors own 40.82% of the company’s stock.

About Electromed

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.